The Differences in Clinicopathologic and Prognostic Characteristics Between Surgically Resected Peripheral and Central Lung Squamous Cell Carcinoma
- 80 Downloads
Abstract
Background
Pulmonary peripheral-type squamous cell carcinoma (p-SqCC) has been increasing in incidence. However, little is known about the clinicopathologic features of p-SqCC. This study aimed to investigate the clinicopathologic characteristics and clinical outcomes of p-SqCC compared with central-type SqCC (c-SqCC) in a large cohort of surgically resected lung SqCC patients with long-term follow-up results.
Methods
The study included 268 patients with SqCC who underwent surgical resection at the authors’ institute from January 1990 to September 2013. The mean follow-up period was 67.1 months. The clinicopathologic and genetic characteristics were investigated in relation to their association with progression-free survival (PFS) and overall survival (OS) based on tumor location.
Results
The study cohort included 120 patients with p-SqCC and 148 patients with c-SqCC. Compared with c-SqCC, p-SqCC was correlated with older age (p = 0.002), female sex (p = 0.033), better performance status (p < 0.001), smaller tumor (p = 0.004), less lymph node metastasis (p < 0.001), and an earlier pathologic stage (p < 0.001). Despite the clinicopathologic differences, tumor location was not significantly correlated with clinical outcomes. For the p-SqCC patients, the multivariate analysis showed a significant correlation of lymphovascular invasion (PFS, p < 0.001; OS, p < 0.001) and lymph node metastasis (p = 0.007; OS, p = 0.022) with poor PFS and OS, but a significant correlation of incomplete tumor resection (PFS, p = 0.009) only with poor PFS.
Conclusions
The clinicopathologic features differed between the p-SqCC and c-SqCC patients. Lymphovascular invasion and lymph node metastasis were independent prognostic factors of p-SqCC. These prognostic factors may be potentially used as indicators for adjuvant therapies to be used with patients who have p-SqCC.
Notes
Acknowledgements
The authors thank Professor Yung-Chie Lee (23 October 1948 to 30 December 2010), a pioneer and leader of thoracic surgery in Taiwan, for his substantial contribution to patient care and surgery. The authors also thank Chih-Hsin Chen for her skillful technical support and clinical data collection. This study was funded by the National Taiwan University Hospital, Taipei, Taiwan (NTUH107-N004038) and the Ministry of Science and Technology, Taiwan (105-2628-B-002-011-MY2).
Disclosure
There are no conflicts of interest.
Supplementary material
References
- 1.American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society; 2016. p 10.Google Scholar
- 2.Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–92.CrossRefGoogle Scholar
- 3.Funai K, Yokose T, Ishii G, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003;27:978–84.CrossRefGoogle Scholar
- 4.Zhang Y, Zheng D, Li Y, Pan Y, Sun Y, Chen H. Comprehensive investigation of clinicopathologic features, oncogenic driver mutations, and immunohistochemical markers in peripheral lung squamous cell carcinoma. J Thorac Dis. 2017;9:4434–40.CrossRefGoogle Scholar
- 5.Hayashi T, Sano H, Egashira R, et al. Difference of morphology and immunophenotype between central and peripheral squamous cell carcinomas of the lung. Biomed Res Int. 2013;2013:157838.Google Scholar
- 6.Saijo T, Ishii G, Nagai K, et al. Differences in clinicopathological and biological features between central-type and peripheral-type squamous cell carcinoma of the lung. Lung Cancer. 2006;52:37–45.CrossRefGoogle Scholar
- 7.Mizushima Y, Yamashita R, Kusajima Y, et al. Prognostic comparison between peripheral and central types of squamous cell carcinoma of the lung in patients undergoing surgical resection. Oncol Rep. 2000;7:319–22.Google Scholar
- 8.Sakurai H, Asamura H, Watanabe S, et al. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg. 2004;78:222–7.CrossRefGoogle Scholar
- 9.Kinoshita T, Ohtsuka T, Hato T, et al. Prognostic factors based on clinicopathological data among the patients with resected peripheral squamous cell carcinomas of the lung. J Thorac Oncol. 2014;9:1779–87.CrossRefGoogle Scholar
- 10.Nagashima T, Sakao Y, Mun M, et al. A clinicopathological study of resected small-sized squamous cell carcinomas of the peripheral lung: prognostic significance of serum carcinoembryonic antigen levels. Ann Thorac Cardiovasc Surg. 2013;19:351–7.CrossRefGoogle Scholar
- 11.Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus, and heart. Lyon: International Agency for Research on Cancer; 2015.Google Scholar
- 12.American Joint Committee on Cancer. Lung. In: Rami-Porta R, Asamura H, Travis WD, Rusch VW (eds) AJCC cancer staging manual, 8th ed. New York: Springer; 2017. pp 431–56.Google Scholar
- 13.Maeda R, Yoshida J, Ishii G, et al. Long-term survival and risk factors for recurrence in stage I non-small cell lung cancer patients with tumors up to 3 cm in maximum dimension. Chest. 2010;138:357–62.CrossRefGoogle Scholar
- 14.Miyoshi K, Moriyama S, Kunitomo T, Nawa S. Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:429–34.CrossRefGoogle Scholar
- 15.Tsuchiya T, Hashizume S, Akamine S, et al. Upstaging by vessel invasion improves the pathology staging system of non-small cell lung cancer. Chest. 2007;132:170–7.CrossRefGoogle Scholar
- 16.Tsuchiya T, Akamine S, Muraoka M, et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341–8.CrossRefGoogle Scholar
- 17.Noma D, Inamura K, Matsuura Y, et al. Prognostic effect of lymphovascular invasion on TNM staging in stage I non-small-cell lung cancer. Clin Lung Cancer. 2018;19:e109–22.CrossRefGoogle Scholar
- 18.Hamanaka R, Yokose T, Sakuma Y, et al. Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer. Diagn Pathol. 2015;10:17.CrossRefGoogle Scholar